Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nofazinlimab (CS1003) in advanced solid tumors
NCT03475251Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nofazinlimab in solid tumor (advanced stage) and colorectal cancer (CRC) (2 arms), sponsored by CStone Pharmaceuticals. Primary endpoint: Number of participants with adverse events. Started May 2018; status: completed.
02
Drugs
nofazinlimab
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03475251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475251.